NS Partners Ltd boosted its position in shares of Allergan PLC. (NYSE:AGN) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,643 shares of the company’s stock after buying an additional 728 shares during the period. Allergan PLC. accounts for about 1.6% of NS Partners Ltd’s portfolio, making the stock its 17th largest position. NS Partners Ltd’s holdings in Allergan PLC. were worth $10,905,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rockshelter Capital Management LLC raised its position in Allergan PLC. by 0.4% in the first quarter. Rockshelter Capital Management LLC now owns 50,149 shares of the company’s stock worth $11,982,000 after buying an additional 188 shares during the last quarter. Dynamic Capital Management Ltd bought a new stake in Allergan PLC. during the first quarter worth about $831,000. United Capital Financial Advisers LLC increased its stake in Allergan PLC. by 25.8% in the first quarter. United Capital Financial Advisers LLC now owns 8,407 shares of the company’s stock worth $2,009,000 after buying an additional 1,722 shares during the period. KCG Holdings Inc. bought a new stake in Allergan PLC. during the first quarter worth about $2,371,000. Finally, Epoch Investment Partners Inc. increased its stake in Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares during the period. 83.63% of the stock is currently owned by institutional investors.
Allergan PLC. (NYSE AGN) traded down 0.35% during mid-day trading on Friday, hitting $223.99. 2,006,235 shares of the stock were exchanged. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a 50 day moving average of $243.31 and a 200-day moving average of $238.68. The stock has a market cap of $74.88 billion, a price-to-earnings ratio of 6.82 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the business posted $3.35 EPS. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts predict that Allergan PLC. will post $16.27 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. Allergan PLC.’s payout ratio is currently 9.95%.
WARNING: “NS Partners Ltd Buys 728 Shares of Allergan PLC. (AGN)” was originally reported by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/ns-partners-ltd-increases-position-in-allergan-plc-agn-updated-updated.html.
A number of analysts recently issued reports on the stock. UBS AG restated a “buy” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research note on Monday, June 26th. Wells Fargo & Company reiterated an “outperform” rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada lifted their target price on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price for the company. in a research note on Wednesday, May 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and a consensus target price of $275.49.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.